[Market Insight] Aju IB Holds Its Own in 3Q Despite KOSDAQ Correction… Accelerating Fund Formation Toward Year-End
Aju IB Reports Cumulative Operating Profit of 27.6 Billion Won for the First Three Quarters… Maintains Profitability Trend
A Series of IPOs, Including Lemon Healthcare and Delicious… Expectations for Capital Recovery
Funds Totaling 335 Billion Won to Be Established This Year, Including the “Ultra-Leap” Scale-Up Program
[Edaily Marketin YunJi Kim Reporter] AJU IB INVESTMENT CO., LTD.(027360)posted relatively solid earnings despite an unstable market environment marked by a correction in the KOSDAQ market and exchange rate fluctuations. Although valuation gains on held assets declined, the company maintained its profit trend, supported by earnings secured in the first half of the year. According to an electronic disclosure by the Financial Supervisory Service on the 16th, AJU IB INVESTMENT CO., LTD. posted a cumulative operating profit of 27.6 billion won on a consolidated basis for the third quarter of this year. As volatility in the KOSDAQ market increased in the third quarter, the stock prices of the listed companies in its portfolio underwent a correction, and fluctuations also occurred in the valuation gains and losses of overseas investment assets. However, the company maintains that this decline in valuation gains is a temporary effect resulting from unrealized gains and losses, and that there has been no change in its core earnings structure derived from fund management.
Despite the challenging market conditions, the investment portfolio continues to yield successful initial public offerings (IPOs). Lemon Healthcare, a digital healthcare platform company, and Delicious, the operator of the business-to-business (B2B) fashion platform “Shinsang Market,” have entered the stock market, and last month, Nexi, a developer of immuno-oncology drugs, also completed its listing. MBD, a precision oncology company based on 3D cell culture, and Davio, a spatial information AI company, are also pursuing IPOs within the year. AJU IB INVESTMENT CO., LTD. plans to determine the timing of its investment recovery by considering post-listing stock price trends and market conditions.
AJU IB INVESTMENT CO., LTD. plans to expand its assets under management by establishing new funds in the fourth quarter of this year. The funds AJU IB INVESTMENT CO., LTD. is pursuing this year include: △Aju Good Ultra-Competitive Scale-Up 2.0(200 billion won), △Aju-Solasta Life Science 5.0 (110 billion won), and △Aju-Solasta Global Frontier Fund (25 billion won), for a combined total of 335 billion won. Of these, the two funds—which are aimed at investing in global biotech and overseas companies—are targeting their first closing by the end of the year.
The new funds are expected to be utilized across a wide range of sectors, from growth-stage investments in domestic deep-tech companies to investments in overseas biotech and high-tech firms. The company anticipates that as the funds’ scale expands, management fee revenue generated during the investment process will also increase, helping to offset the volatility in valuation gains and losses of investment assets, which can fluctuate significantly depending on market conditions.
The company is also broadening its investment targets, focusing on AI and global growth companies. This year, AJU IB INVESTMENT CO., LTD. expanded its investments in AI semiconductors, infrastructure, and robotics, while also investing in global companies such as the U.S. data and AI firm Databricks. In the biotech sector, it is diversifying its portfolio by resuming new investments in both domestic and international companies.
An official from AJU IB INVESTMENT CO., LTD. stated, “Although third-quarter earnings were impacted by a decline in valuation gains due to market fluctuations, we are maintaining profitability based on the profits secured in the first half of the year,” adding, “We plan to strengthen our management fee base by establishing new funds within the year and continue investing primarily in AI and high-quality global companies.”
LGELECTRONICS has invested approximately 3.6 trillion won in research and development (R&D) through the third quarter of this year. This represents an increase of more than 27% compared to the same pe…
LF achieved both revenue growth and improved profitability in the third quarter, driven by balanced growth across its in-house and imported fashion and beauty brands. LF(093050)According to the quarte…
Boryung(003850)and Celltrion Pharm Inc. will jointly market the “Nesina” and “Actos” product lines for the treatment of type 2 diabetes. The strategy is to expand their presence in the domestic diabet…